German Parliament passes comprehensive health policy packageThe Bundestag passed a comprehensive health policy package on Thursday, FAZ (p1 and 15), Süddeutsche Zeitung (SZ) (p7) and Die Welt (p10) report on Friday. The aim is for patients to be seen more quickly by community doctors and to accelerate digitalisation in the healthcare system.
CureVac set to float in U.S.The stock flotation of German biotech CureVac will take place in the U.S. but not in Germany, leading investor Dietmar Hopp told FAZ on Sunday (p19).
Pharma lobby vfa to have single managementThe current chair of German pharma lobby vfa , Han Steutel, country manager of Bristol-Myers Squibb, will soon also be its managing director, FAZ reported on Thursday (p24) (APMHE 62231).
Merck KGaA in patent dispute with Japanese competitor on liquid crystal mixturesMerck KGaA has set aside between €10 and €100 million ("a double digit million euro amount") because of a patent dispute on liquid crystal mixtures with its Japanese competitor JNC, FAZ reported on Tuesday (p18)
Grünenthal targets U.S. pain marketGerman pain specialist Grünenthal is planning to increase sales of launch pain patch Qutenza (capsaicin) and to launch neridronate in complex regional pain syndrome (CRPS) in the U.S., chief executive Gabriel Bartschi told FAZ on Wednesday (p18) (APMHE 62250).
Merz Pharma fully focused on aestheticsMerz Pharma is focusing its business on aesthetic products, a shift decided more than five years ago in anticipation of the loss of patent on its former best-selling Alzheimer's drug Axura (memantine), FAZ reported on Tuesday (p33).
Roche and AC immune stop development of crenezumab for Alzheimer'sRoche and AC immune have stopped development of Alzheimer's drug candidate crenezumab (APMHE 61634), Sueddeutsche Zeitung (SZ) reported on Tuesday (p14).
Sandoz' CEO resignsSandoz chief executive Richard Francis has unexpectedly resigned and will leave the Novartis group at the end of March, reports FAZ on Friday (p) (APMHE 62255).
Big data, AI and Crispr in medicine trigger hopes and fearsThe use of big data analysis, artificial intelligence and genetic engineering generate major hopes and fears, reported Handelsblatt on Monday (p16-17).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.